You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和黃醫藥(00013.HK):蘇泰達獲納入新版國家醫保藥品目錄 愛優特獲續約
阿思達克 12-03 12:26
和黃醫藥(00013.HK)公佈,經過與國家醫保局的2021年醫保談判,蘇泰達獲納入自2022年1月1日起生效的新版醫保藥品目錄中,愛優特則獲續約。 愛優特於去年1月1日首獲納入醫保藥品目錄,用於治療轉移性結直腸癌。蘇泰達於同年12月在中國獲批準用於治療晚期非胰腺神經內分泌瘤,並於2021年6月獲批準用於治療晚期胰腺神經內分泌瘤。 和黃醫藥第三個抗腫瘤藥物沃瑞沙是中國首個且唯一獲批的MET抑制劑,用於治療伴有MET外顯子14跳變的非小細胞肺癌患者。沃瑞沙亦參與了與國家醫保局的2021年醫保談判,但和黃醫藥及其沃瑞沙合作夥伴阿斯利康決定不進入2022年版醫保藥品目錄。明年於醫保藥品目錄調整前,雙方將再次評估這一立場。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account